Published Date: 01 Aug 2025
A study published in the International Journal of Radiation Oncology*Biology*Physics demonstrates that clinicopathology (CP) based risk assessment frequently fails to accurately assess recurrence risk and radiation therapy ...
Read Full News1.
Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC
2.
Cancer during young adulthood carries long-term mental toll, study finds
3.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
4.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
5.
Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.
1.
Beating Cancer Fatigue The Most Effective Exercise Strategies for Breast Cancer Survivors
2.
Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment
3.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
4.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
5.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
2.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
4.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation